Gossamer Bio prices $276M IPO

Gossamer Bio Inc. (NASDAQ:GOSS) raised $276 million in an upsized IPO priced late Thursday. Trading is to begin Friday.

Launched officially just 13 months ago by ex-Receptos Inc. executives, Gossamer is developing therapeutics for inflammation, immune disorders and oncology. In the IPO, the company sold 17.3 million shares at $16, giving it a valuation just above $1 billion...